These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19604081)

  • 21. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.
    Eap CB; Guentert TW; Schãublin-Loidl M; Stabl M; Koeb L; Powell K; Baumann P
    Clin Pharmacol Ther; 1996 Mar; 59(3):322-31. PubMed ID: 8653995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Partitioning of thioridazine and mesoridazine in human blood fractions.
    Dinovo EC; Pollak H; Gottschalk LA
    Methods Find Exp Clin Pharmacol; 1984 Mar; 6(3):143-6. PubMed ID: 6748818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
    LLerena A; de la Rubia A; Berecz R; Dorado P
    Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio.
    Ohara K; Tanabu S; Yoshida K; Ishibashi K; Ikemoto K; Shibuya H
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):945-9. PubMed ID: 14499311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
    Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
    Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
    Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
    Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
    van der Weide K; van der Weide J
    J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.
    Dorado P; Berecz R; Peñas-Lledó EM; Cáceres MC; Llerena A
    Curr Drug Targets; 2006 Dec; 7(12):1671-80. PubMed ID: 17168842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients.
    Shvartsburd A; Nwokeafor V; Smith RC
    Psychopharmacology (Berl); 1984; 82(1-2):55-61. PubMed ID: 6420831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
    Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
    Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
    Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
    Bork JA; Rogers T; Wedlund PJ; de Leon J
    J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a metabolite of thioridazine and mesoridazine from human plasma.
    Gruenke LD; Craig JC
    Res Commun Chem Pathol Pharmacol; 1975 Feb; 10(2):221-5. PubMed ID: 1162173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing.
    Cai WM; Nikoloff DM; Pan RM; de Leon J; Fanti P; Fairchild M; Koch WH; Wedlund PJ
    Pharmacogenomics J; 2006; 6(5):343-50. PubMed ID: 16550211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
    Molden E; Waade RB; Hoff M; Haslemo T
    Basic Clin Pharmacol Toxicol; 2016 Nov; 119(5):470-475. PubMed ID: 27145399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
    Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
    Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.